Bluebird Bio Seeks Shareholder Approval for Take-Private Deal; Unity Bio Eyes Strategic Review; Mersana to Cut Over 50% of Workforce

Bluebird Bio urged its shareholders to approve a proposed take-private transaction, while Unity Biotechnology initiated a strategic review of its operations, and Mersana Therapeutics revealed plans to reduce its workforce significantly. Specifically, Bluebird Bio has asked its shareholders to support a deal that could be finalized very soon. Meanwhile, Unity Biotechnology will evaluate its current business strategies, resource allocation, and potential partnerships. In a separate development, Mersana Therapeutics announced it will lay off over 50% of its employees as part of a restructuring effort.

Newsflash | Powered by GeneOnline AI
Date: May 6, 2025

Author

Mark Chiang